Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04987203 |
|
Recruitment Status :
Recruiting
First Posted : August 3, 2021
Last Update Posted : March 20, 2023
|
Sponsor:
AVEO Pharmaceuticals, Inc.
Collaborators:
Parexel
Bristol-Myers Squibb
Information provided by (Responsible Party):
AVEO Pharmaceuticals, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | August 1, 2024 |
| Estimated Study Completion Date : | August 1, 2025 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):